An observational study in Lung Transplant Failure and Rejection and Chronic Lung Allograft Dysfunction, sponsored by Paris Translational Research Center for Organ Transplantation. Enrolling by invitation at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-16.
Sponsored by Paris Translational Research Center for Organ Transplantation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
For individuals with ESLD, lung transplantation is the best, or only treatment option with increased pulmonary function and quality of life. The forced expiratory volume in one second (FEV1) is the standard to monitor the lung function after transplantation. The goal of this study is to identify and validate the FEV1 trajectories after lung transplantation, as well as their determinants and outcomes, using an international cohort of lung recipients.
Chronic lung diseases affect about 500 million individuals and are the third leading cause of death worldwide, accounting for 7% of all mortality. They drive the growing number of individuals with end stage lung disease (ESLD), a public health issue with socioeconomic consequences.
For individuals with ESLD, lung transplantation is the best, or only treatment option with increased pulmonary function and quality of life. Lung recipients remain however particularly at risk, with a median patient survival of around five years, which is much lower than other organ recipients, such as kidney, heart or liver recipients. Adequate monitoring of the lung recipient is therefore crucial to optimize the allograft longevity.
The forced expiratory volume in one second (FEV1) is the standard to monitor the lung function after transplantation, and is used to evaluate the stage and severity of lung allograft diseases. However, according to a literature review we performed, the very few studies that have investigated the FEV1 evolution, and its relationship with outcomes such as death or chronic lung allograft dysfunction, were commonly based on cohort with insufficient data variety and completeness. Importantly, these studies lacked external validation, multidimensional approach, and none has attempted to identify the main profiles of FEV1 trajectories and their associated parameters. As such, the determinants and long-term outcomes of FEV1 trajectories are still poorly understood.
A multidimensional, trajectory-based approach may help unveil clinically relevant organ function profiles among lung recipients. Indeed, several studies have shown the potential existence of underlying trajectories of transplanted organs' function and diseases, and their associations with outcomes and relevance for patient management, such as in kidney or heart transplantation. These studies used a unsupervised approach, which permitted to erase any preconceived clinical ideas. Overall, this approach has shown its value in several medical specialties, in particular in image analysis, oncology, or cardiology.
Therefore, the goal of this study was to identify and validate the FEV1 trajectories after lung transplantation, as well as their determinants and outcomes, using an international cohort of lung recipients, with a protocol-based collection of FEV1 repeated assessments and clinical, biological, histological and immunological data.
Paris Translational Research Center for Organ Transplantation is the lead sponsor of 31 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients who received a bilateral lung transplantation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Lung recipients from Foch hospital, Suresnes, France
Lung recipients from Bichat hospital, Paris, France
Lung recipients from Nantes hospital, Nantes, France
Lung recipients from Pulmonary hypertension center, San Antonio, Texas, US
Lung recipients from Marie-Lannelongue hospital, Le Plessis-Robinson, France
Lung recipients from Bordeaux hospital, Nantes, France
Lung recipients from Marseille hospital, Marseille, France
Lung recipients from Toulouse hospital, Toulouse, France
Lung recipients from Strasbourg hospital, Strasbourg, France
Lung recipients from Grenoble hospital, Grenoble, France
Lung recipients from Strasbourg hospital, Paris, France
Lung recipients from Hospital center Mayenne North, Mayenne, France
FEV1 trajectories
FEV1 trajectories of the lung recipient
Time frame: Up to 10 years after lung transplantation
Patient death
Patient death after lung transplantation
Time frame: Up to 10 years after lung transplantation
Allograft failure
Allograft failure after lung transplantation
Time frame: Up to 10 years after lung transplantation
Chronic lung allograft dysfunction
CLAD after lung transplantation
Time frame: Up to 10 years after lung transplantation
Plan to share: Yes — Deidentified data may be shared for research purpose upon reasonable request.
Supporting information: Study protocol, Statistical analysis plan
Time frame: After publication
Access criteria: Via email to the corresponding author
Ran from Jan 2020 to primary completion in Jan 2021, 12 months.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rejection, Psychology
Paris Translational Research Center for Organ Transplantation